Xpert MTB/RIF Ultra Trace Results: Decision Support for the Treatment of Extrapulmonary Tuberculosis in Low TB Burden Countries.
Aurélie GuillouzouicAlice GaudartEve TessierKarine RissoFarida HamdadCorentine AlauzetPierre VaillantChristelle KoebelLoïc KassegneRachel ChenouardPierre AbgueguenCécile Le BrunSimon JamardRaphaël LecomteMaeva LefebvrePascale BemerPublished in: Journal of clinical medicine (2023)
A total of 52 patients were included, with a severe form in 22/52 (42.3%) cases. Culture was positive for MTBC in 33/46 (71.7%) cases. Histological analysis showed granulomas in 36/45 (80.0%) cases. An Ultra trace result with a presumptive diagnosis of TB led to the decision to treat 41/52 (78.8%) patients. All patients were started on first-line anti-TB therapy (median duration of 6.1 months), with a favorable outcome in 31/35 (88.6%) patients. The presence of a small amount of MTBC genome in EPTB is a sufficient argument to treat patients across a large region of France.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- stem cells
- peritoneal dialysis
- emergency department
- gene expression
- patient reported
- early onset
- hepatitis c virus
- electronic health record
- risk assessment
- pulmonary tuberculosis
- smoking cessation
- data analysis
- antiretroviral therapy